Muromonab-CD3: Difference between revisions
m clean up- spelling "et al." and gen fixes using AWB |
+ CAS, + formula, + molecular mass |
||
| Line 4: | Line 4: | ||
| source = <!-- organism from which derived --> |
| source = <!-- organism from which derived --> |
||
| target = <!-- antigen --> |
| target = <!-- antigen --> |
||
| CAS_number = |
| CAS_number = 140608-64-6 |
||
| ATC_prefix = L04 |
| ATC_prefix = L04 |
||
| ATC_suffix = AA02 |
| ATC_suffix = AA02 |
||
| PubChem = |
| PubChem = |
||
| DrugBank = |
| DrugBank = |
||
| chemical_formula = |
| chemical_formula = C<sub>6460</sub>H<sub>9946</sub>N<sub>1720</sub>O<sub>2043</sub>S<sub>56</sub> |
||
| molecular_weight = |
| molecular_weight = 146091.29 |
||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
Revision as of 22:57, 1 August 2009
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C6460H9946N1720O2043S56 |
| Molar mass | 146091.29 |
OKT3 (also called muromonab) is an immunosuppressant drug given to reduce acute rejection in transplant patients.[1] A major milestone in the prevention of acute allograft rejection was achieved with the development of the mAb OKT3, the first mAb to be approved for clinical use in humans.
It has also been investigated for use in treating T-cell acute lymphoblastic leukemia.[2]
Structure and function
OKT3 is a murine monoclonal IgG2a antibody that reacts with the T cell receptor- CD3 complex (specifically the epsilon chain of the T cell receptor) on the surface of circulating human T cells. The T cell has 2 molecules on its surface which function primarily in antigen recognition. These antigen recognition structures are associated with 3 polypeptide chains (the CD-3 complex). The CD-3 complex transduces the signal for the T cell to react to the foreign antigen, proliferate, and attack the foreign matter.
OKT3 is a monoclonal antibody that specifically reacts with the T-3 complex by blocking the function of T cells.
The binding of murine MAb OKT3 to CD3 can activate T cells - cytokine release syndrome - resulting in a number of side effects, including pyrexia, myalgia, nausea and diarrhoea.
References
- ^ Midtvedt K, Fauchald P, Lien B; et al. (2003). "Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection". Clinical transplantation. 17 (1): 69–74. PMID 12588325.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ Gramatzki M, Burger R, Strobel G; et al. (1995). "Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2 responsiveness". Leukemia. 9 (3): 382–90. PMID 7885036.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |